Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

BridgeBio Pharma (BBIO) Gross Profit: 2017-2024

Historic Gross Profit for BridgeBio Pharma (BBIO) over the last 8 years, with Dec 2024 value amounting to $218.0 million.

  • BridgeBio Pharma's Gross Profit rose 5248.50% to $114.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $338.8 million, marking a year-over-year increase of 57.33%. This contributed to the annual value of $218.0 million for FY2024, which is 3079.58% up from last year.
  • BridgeBio Pharma's Gross Profit amounted to $218.0 million in FY2024, which was up 3,079.58% from $6.9 million recorded in FY2023.
  • In the past 5 years, BridgeBio Pharma's Gross Profit ranged from a high of $218.0 million in FY2024 and a low of $6.9 million during FY2023.
  • For the 3-year period, BridgeBio Pharma's Gross Profit averaged around $99.7 million, with its median value being $74.2 million (2022).
  • In the last 5 years, BridgeBio Pharma's Gross Profit crashed by 90.76% in 2023 and then skyrocketed by 3,079.58% in 2024.
  • BridgeBio Pharma's Gross Profit (Yearly) stood at $8.2 million in 2020, then spiked by 541.12% to $52.9 million in 2021, then surged by 40.33% to $74.2 million in 2022, then crashed by 90.76% to $6.9 million in 2023, then surged by 3,079.58% to $218.0 million in 2024.